B7-33 is a single-chain peptide. It is derived from a naturally occurring compound called H2-Relaxin. Relaxin proteins are a family of four proteins comprising Relaxin, Insulin-like peptide 3, H3-relaxin, and insulin-like peptide 5. They all possess pleiotropic actions impacting the cardiovascular system, musculoskeletal system, reproduction system, etc. These proteins perform these actions through four types of receptors, namely (RXFP1/2 and RXFP3/4). Various ligands, such as cAMP and corticotropin-releasing hormone, stimulate these receptors. All these agonists can express antioxidant, anti-inflammatory, and wound healing properties. However, Relaxin, in addition to possessing above mentioned properties, also exhibits antihypertrophic, vasodilator, and angiogenic properties. This is why Relaxin and its derivatives have been of great interest for researchers to explore its further benefits. B7-33 preferentially stimulates the pERK pathway over the cAMP pathway. The pERK pathway regulates cell cycle arrest in the G1 phase and has been implicated in several diseases like Alzheimer's and Crutzfeld-Jacob. By blocking cell cycle progression in cells with RXFP1 receptors, B7-33 exercises its anti-fibrotic effects through the ability to stimulate RXFP1-angiotensin II type 2 receptor heterodimering, which activates pERK1/2 signaling and, thus triggers the increased production of the collagen-degrading enzyme matrix metalloproteinase (MMP) -2. 4. B7-33 Benefits B7-33 is a revolutionary anti-inflammatory, antioxidant, and wound healing agent. It's also a vasodilator and a blood vessel growth stimulator. Additionally, this product has very potent anti-fibrotic effects, so it can be used to treat acute heart failure and other fibrotic disorders. It treats Alzheimer Disease (AD) and Creutzfeldt-Jakob Disease (CJD). B7-33 is much better than its "parent peptide" named H2-Relaxin because B7-33 doesn't activate cAMP pathway. By non-activating cAMP, B7-33 avoids basically all of the undesired effects normally found in H2-Relaxin, but still keeps all of H2-Relaxin's positive effects to the user's organism. B7-33 reduces the long-term scarring following heart damage, and it's the first treatment approved for acute heart failure in the last 20 years. It protects against heart failure, therefore improving heart function and avoiding long-term symptoms and complications. It also reduces in approximately 50% the post-injury heart scarring. It benefits people with asthma, lung fibrosis and lung inflammation, as well as people with kidney conditions. Much differently from H2-Relaxin, B7-33 does not promote any kind of tumor growth, even when administered in higher doses (that's why B7-33 is absolutely safe). This product offers great protection against endothelial dysfunction and treats long-term scarring in general. Its mechanism of action causes vasorelaxation that is useful to treat certain cardiovascular conditions as well as preeclampsia of pregnancy, even in severe cases. And, when it comes to pregnancy, B7-33 improves blood supply between mother and child (fetus), which makes it safer for women to carry their children to term in a manner that is secure for both. This product helps the body to accept implants and foreign objects in general, preventing the organism from naturally rejecting them. This acceptance by the body is very welcome in cases of medical device implantations, for instance. Lastly, B7-33 reduces blood pressure and protects vasculature. .

Customization:	Available
Powder:	Yes
Customized:	Customized

Fat Burner Peptide Raw Powder B7-33 (H2 relaxin) Releasing Hormone Peptide

Product Description

Company Info.

Basic Info.

Product Description

Send your message to this supplier

Find Similar Products By Category

Related Categories

Hot Searches